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7 CURRENTOPINION Mitral valve replacement in patients under
65 years of age: mechanical or biological valves? Copyright 
www.co-cardiology.comDavid C. Reineke, Paul Philipp Heinisch, Bernhard Winkler,
Lars Englberger, and Thierry P. CarrelPurpose of review
There is controversy regarding the optimal choice of prosthetic valves in patients less than 65 years of age
requiring mitral valve replacement (MVR). Recently, trends for valve replacement are moving towards
biological prosthesis also in younger patients, which is justified by the fact that a later valve-in-valve
procedure is feasible in the case of degeneration of the tissue valve. This strategy is increasingly
recommended in aortic valve surgery but is questionable for MVR. The purpose of this review is to evaluate
current guidelines and analyse evidence for biological MVR in patients under 65 years.
Recent findings
There are differences between guidelines of the American Heart Association and those of the European
Society of Cardiology concerning the choice of prostheses in patients undergoing MVR. Although the
European Society of Cardiology recommends a mechanical mitral valve in patients under 65 years of age,
the American Heart Association does not provide detailed advice for these patients. Mitral valve
replacement with biological valves in patients under 65 years is associated with higher rates of reoperation
due to structural valve deterioration. In addition, several studies showed a decreased survival after
biological MVR.
Summary
Evidence for biological MVR in patients less than 65 years without comorbidities or contraindication for
oral anticoagulation does not exist. Recommendations for patients less than 65 years of age should not be
blurred by current ‘en-vogue’ methods for promising but not yet proven valve-in-valve strategies.
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The use of biological or mechanical prosthetic heart
valves for mitral valve disease is still a subject
of debate in patients between the age of 60 and
70 years. According to the common evidence,
mechanical valves are mainly selected for younger
patients to avoid structural valve deterioration
(SVD) [1
&
,2]. When surgical treatment of mitral
valve disease is necessary, replacement of the valve
is only performed when repair is not feasible or may
expose the patient to an unacceptable risk of re-
operation. According to the guidelines of the
European Society of Cardiology, repair of the mitral
valve is themethod of choice in the largemajority of
patients [3
&&
,4]. When preservation of the native
valve is, however, not possible, mitral valve replace-
ment (MVR) can be achieved by either a mechanical
or a biological valve prosthesis. The current guide-
lines uniformly recommend mechanical MVR in© 2015 Wolters Kluwer patients under 60 years of age. In patients between
60 and 70 years of age, recommendations are, how-
ever, conflicting. Similarly to what is happening in
aortic valve surgery, there is currently a trend to
move towards more biological MVR – also in
patients under 65 years of age. Justification for this
approach is that the future option for later valve-
in-valve procedure (in the case of SVD) is realistic. In
addition, the last generation of pericardial tissue
valves is expected to have a better long-term dura-
bility [4–7].Health, Inc. All rights reserved.
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KEY POINTS
 Patients less than 65 years without comorbidities or
contraindication to oral anticoagulation should receive
a mechanical valve when the mitral valve has to
be replaced.
 Valve-in-valve strategy is not proven to justify biological
MVR at a younger age. Recommendations should not
be blurred by current ‘en-vogue’ methods.
Mitral valve replacement in patients under 65 years of age Reineke et al.In the literature, biological MVR in patients
under 65 years of age, however, results in higher
rates of reoperation and decreased survival [1
&
,2].
Valve selection is always a balanced decision, taking
into account the pros and cons of both types of
prostheses: limited durability of tissue valves and
life-long requirement for anticoagulation with
subsequent increased risk of bleeding and throm-
boembolic complications after mechanical valve
replacement. Furthermore, the selection of the valve
prosthesis depends on various patient-related fac-
tors, such as age of implantation, durability of the
valve, compliance with long-term anticoagulation,
and the patient’s preferences.CURRENT GUIDELINES
In the 2014 guidelines (Table 1), the American Heart
Association (AHA) recommendsmechanical MVR in
patients less than 60 years of age who do not have
a contraindication to long-term anticoagulation
[1
&
,2]. In patients between 60 and 70 years of age,
both biological and mechanical MVR are acceptable
options according to these guidelines. Both recom-
mendations are justified with a level of evidence
(LOE) B and class of recommendation (COR) IIa. For
patients older than 70 years, a biological valve pros-
thesis is recommended (LOE: B/COR: IIa). The only
class I recommendation concerning type of prosthe-
sis is the choice of a tissue valve for MVR independ-
ently of age in the case that anticoagulation is
contraindicated (LOE: C/COR: I) [3
&&
,4].
In the 2012 guidelines of the European Society
of Cardiology (ESC) (Table 1), mechanical MVR is
indicated for all patients with a risk for accelerated
SVD and in patients who already have a mechanical
prosthesis in another position (LOE: C/COR: I)
[1
&
,4–7]. Unlike the 2014 AHA guidelines, the
2012 ESC guidelines precisely state that mechanical
MVR should be considered in patients under 65
years of age (LOE: C/COR: IIa). The AHA guidelines
are less precise and only mention a range of 10 years
between 60 and 70 years of patient age where any
decision is appropriate [1
&
,2]. In patients with an Copyright © 2015 Wolters Kluwe
0268-4705 Copyright  2015 Wolters Kluwer Health, Inc. All rights reseincreased risk of SVD (e.g., end-stage renal disease
[ESRD] or hyperparathyroidism), mechanical MVR
is recommended (LOE: C/COR: I). Only the 2012
ESC guidelines suggest amechanical prosthesis as an
optimal choice in patients with a reasonable life
expectancy for whom future reoperation due to
SVD would be associated with a high risk (LOE:
C/COR: IIa). In both the guidelines, the patient’s
choice is considered a class I recommendation [1
&
,4].CURRENT EVIDENCE
The choice between a mechanical and a biological
valve in adults is generally determined by the assess-
ment of the risks of anticoagulation-related bleeding
and thromboembolism in patients with a mechan-
ical valve against the risk of SVD in those patients
with a tissue valve. In addition, the patient’s
opinion and his estimated quality of life as health-
care preferences are considered. Structural valve
degeneration is clearly dependent on the age at
implantation and the position of the tissue valve
(mitral earlier than aortic).
Hammermeister et al. [8] reported a long-term
follow-up of 181 patients who underwent biological
MVR with the Carpentier–Edwards PERIMOUNT
mitral prosthesis (Edwards, Irvine, CA, USA): a very
low rate of reoperation because of SVD was observed
in patients who received the tissue valve at an age
lower than 65 years (freedom from reoperation of
76.8% at 15 years). In contrast, when MVR was
performed in patients younger than 65 years, they
had a freedom of only 49.5 and 25.1% from re-
operation because of SVD at 15 and 20 years, respec-
tively.
In one of the most cited studies, the Edinburgh
heart valve trial, the mitral valve was replaced in
261 patients, the aortic in 211, and both valves in
61 patients [9]. After 20 years of follow-up, no
difference between the survival rates of the two
groups was observed. The reoperation rate was
higher for the biological group, whereas more
patients with a mechanical heart valve experienced
a bleeding complication due to anticoagulation.
In the randomized Veterans Affairs trial, 575
men received either a mechanical Bjork–Shiley or
a biological Hancock prosthesis (394 aortic valve
replacement and 181 MVR) [8]. After a follow-up
of 15 years, survival rate was higher in the group of
patients who received mechanical MVR. Bleeding
complications were more frequent in patients with
mechanical valves, but no significant difference was
observed for thromboembolic and infectious com-
plications. As expected, SVD occurred more fre-
quently in younger patients who received a tissue
valve: in 26% of patients who received aortic valver Health, Inc. All rights reserved.
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Table 1. Comparison between guidelines for the treatment of patients with valvular heart disease of the American Heart
Association/American College of Cardiology and the European Society of Cardiology
Guidelines
AHA/ACC ESC
COR LOE Age COR LOE Age
Choice of valve inter-
vention should be a
shared decision pro-
cess with the patients
I C No limitation I C No limitation
Type of valve prosthesis
is recommended
according to the
desire of the informed
patient
I C No limitation I N No limitation
Mechanical prosthetic
mitral valve
IIa B <60 IIa C <65
Biological prosthetic
mitral valve
IIa B >70 IIa C >70
Mechanical prosthesis
in patients at risk for
accelerated SVD
n/c n/c I C <40
Mechanical prosthesis
in patients already
under anticoagulation
for a mechanical
valve prosthesis
n/c n/c I C No limitation
Bioprosthesis is recom-
mended for patients
at any age for whom
anticoagulation is
contraindicated
I C No limitation I C No limitation
Either a mechanical or
a bioprosthetic valve
is reasonable
IIa B 60–70 n/c n/c
Bioprosthesis in patients
with desire to have
children
n/c n/c IIa C No limitation
ACC, American College of Cardiology; AHA, American Heart Association; COR, class of recommendation; LOE, level of evidence; n/c, not clarified; SVD,
structural valve deterioration.
Valvular heart diseasereplacementwith a tissue valve under 65 years of age
but 44% after MVR with a tissue valve in patients
under 65 years of age.
A retrospective study by Hanania [10] in a
homogeneous patient cohort, separated by the year
of intervention, length of follow-up, and age at the
time of surgery between 60 and 70 years, showed
similar results to those reported by the Veterans
Affairs trial. Among the 574 patients enrolled, a
subgroup received 184 prosthetic mitral valves
(99 mechanical and 85 biological). Overall survival
was better in patients receiving mechanical pros-
thetic valves.
These reports can be interpreted as a confir-
mation of the European guidelines that consider
the cutoff limit of 65 years to recommend a mech-
anical prosthesis (<65) or a biological prosthesis
(>65). Copyright © 2015 Wolters Kluwer 
148 www.co-cardiology.comBLEEDING
Patients who undergo valve replacement with a
mechanical prosthesis receive life-long oral antico-
agulation therapy to prevent thromboembolic
events. This treatment is associated with an
increased risk of bleeding [11]. The absolute risk
of anticoagulation-related intracranial haemor-
rhage is between 0.3 and 1% per year, compared
with a spontaneous rate of 0.15% per year [12]. In
addition, these patients have an annual risk of
thromboembolic events of 1–2% compared with
0.7% in those patients who receive a tissue valve
[3
&&
].
Kaneko et al. estimated the freedom from
major bleeding in patients under 65 years of age
after mechanical MVR as 87.2, 79.2, and 71.2%
at 5, 10, and 15 years, respectively [2]. In the group
with biological MVR, freedom from major bleedingHealth, Inc. All rights reserved.
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Mitral valve replacement in patients under 65 years of age Reineke et al.at 5, 10, and 15 years was 91.1, 85.0, and 77.9%,
respectively.
Surprisingly, these differences were not statisti-
cally significant [2] and the results were confirmed
in other studies [13]. In patients older than 65 years,
the use of biological MVR has been supported by the
low rate of SVD and haemorrhagic complications
[14,15].RENAL INSUFFICIENCY
Chronic renal disease is associated with a higher
incidence of cardiovascular calcifications and
represents an independent risk factor for all-cause
mortality [16]. Incidence ofmalnutrition, inflamma-
tory state, atherosclerosis, and calcium–phosphorus
metabolic disorders with substantial calcifications of
native heart valves is significantly higher in patients
with ESRD [17].
The reduced life expectancy of these patients –
when compared with the normal population –
makes the choice of the optimal valve prosthesis a
subject to debate.
The traditional view of the American College of
Cardiology/AHAwas that tissue valves may undergo
accelerated calcification leading to premature SVD
in patients with ESRD. Therefore, mechanical valves
have been recommended as the better choice in
these patients. In 2004, the Canadian Cardiovascu-
lar Society Consensus on Surgical Management of
Valvular Heart Disease recommended bioprostheses
for valvular replacement surgery in patients with
ESRD because of their significantly reduced life
expectancy [18]. Nevertheless, there is still contro-
versy regarding optimal recommendation for valve
selection in patients with ESRD requiring dialysis.
Zhibing et al. [19
&
] reported no significant difference
of early and late mortality in patients on chronic
renal replacement therapy independently of the
valve implanted. In addition, no premature SVD
was reported after biological valve replacement [19
&
].
The 2012 ESC guidelines acknowledge in this
specific situation that tissue valve should be con-
sidered in patients whose life expectancy is lower
than the presumed durability of the prosthesis.
Furthermore, biological valve replacement is recom-
mended in patients in whom comorbidities may
necessitate further surgical procedures, and in
patients with increased risk of bleeding [4]. Patients
with chronic renal failure have an impaired long-
term survival after heart valve replacement regard-
less of the implanted prosthesis (biological or mech-
anical). This observation and an increased risk of
complications (bleeding, thromboembolism, and
infection) with mechanical valves may favour the
choice of a tissue valve in this situation [19
&
]. Copyright © 2015 Wolters Kluwe
0268-4705 Copyright  2015 Wolters Kluwer Health, Inc. All rights reseThe 2006 AHA guidelines already recognized
that mechanical valve replacement may be a source
of problems in patients with renal failure and
those on dialysis. Chronic dialysis patients tend to
have more haemorrhagic complications. Therefore,
these patients, when they receive long-term anti-
coagulation therapy, may be at an increased risk for
bleeding, and current recommendations clearly
favour a bioprosthesis in patients with ESRD
[18,20–22]. The limited life expectancy in patients
with ESRD, even under the age of 65 years, justifies
the implantation of a bioprosthetic valve [23,24].VALVE CHOICE IN WOMEN OF
CHILD-BEARING AGE
The selection of the ideal prosthesis is a major
difficulty in patients with the desire to have chil-
dren. All types of prosthetic valve can cause signifi-
cant problems during pregnancy. The 2012 ECS
guidelines emphasized the high risk of thromboem-
bolic complications with a mechanical prosthesis
during pregnancy despite correct anticoagulation
[4,25]. A planned pregnancy is considered a class
IIb and a level C evidence indication for a biological
valve [4,23].
The rapid development of SVD in this age group,
however, is a limiting factor to the durability of the
tissue valves, and controversy exists as to whether
pregnancy per se may lead to accelerated SVD
[18,20,22]. These patients will all need a reoperation
if they received a tissue valve, but the risk of peri-
operative mortality is between 0 and 5%. In com-
parison, the spontaneous risk of mortality in
pregnant patients with a mechanical valve is esti-
mated to be around 1–4% [23].
The risks of anticoagulation should be
thoroughly discussed with the patient when preg-
nancy occurs. In the first trimester, the respective
maternal and fetal risks (e.g., teratogenicity) should
be carefully assessed. During the second and
third trimesters, phenprocoumon is favoured until
the 36th week. A recent review of the literature
confirmed the low risk of valve thrombosis with
oral anticoagulation throughout pregnancy (2.4%,
7/287 pregnancies) compared with unfractionated
heparin (UFH) in the first trimester (10.3%, 16/156
pregnancies) [25]. From the 36th week, phenpro-
coumon should be replaced by heparin until deliv-
ery [23].CONCLUSION
The survival rates of patients following mechanical
and biological valve replacement are comparable.
The current trend in the literature ismoving towardsr Health, Inc. All rights reserved.
rved. www.co-cardiology.com 149
Valvular heart diseasethe implantation of bioprosthetic valves in younger
patients (<65 years of age). This trend is justified by
the improved durability of the current generation of
tissue valves and the technical feasibility of a sub-
sequent valve-in-valve procedure (in the case of
degeneration of the tissue valve) to avoid open-heart
surgery. Although this might appear reasonable in
high-risk and elderly patients, this approach is
not supported by scientific evidence in younger
patients, especially not for those without comorbid-
ities or contraindication for anticoagulation. There
are, however, certain patient groups under 65 years
of age in whom tissue valve is a good option for
MVR: those with contraindication to anticoagula-
tion, those with ESRD, and, of course, women with
the wish for pregnancy.
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